Thursday 21 November 2024

The Pharma Letter Podcast — Episode 26 — CRO sector surges in bio revolution

Biotechnology
Simon Wentworth
24 October 2023
episode26-large-podcast

More on this story...

Pharmaceutical
Two new hires at Asia-Pacific-focused CRO Novotech
13 October 2023
Biotechnology
Singaporean CRO Novotech appoints new chief medical officer
4 October 2023
Pharmaceutical
Growing CDMO appoints new president of Novasep business
19 October 2023
Pharmaceutical
Data show outsourcing growth set to continue in future
1 December 2023


More ones to watch >


Today's issue

EC approval for Pfizer’s Hympavzi
Biotechnology
EC approval for Pfizer’s Hympavzi
20 November 2024
Biotechnology
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Pharmaceutical
Ascentage's lisaftoclax accepted for priority review in China
20 November 2024
Biosimilars
Xbrane and Intas to jointly develop Opdivo biosimilar
20 November 2024
Pharmaceutical
Chris Boshoff takes on new role at Pfizer
20 November 2024
Biotechnology
Two Neds better than one in Jupiter’s world of moons
20 November 2024
Pharmaceutical
Cytokinetics and Bayer ink deal for aficamten in Japan
20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.




More Features in Biotechnology

EC approval for Pfizer’s Hympavzi
20 November 2024
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Two Neds better than one in Jupiter’s world of moons
20 November 2024
JAK inhibitors redefining atopic dermatitis treatment
20 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze